FDA clears bioabsorbable urethral sling:
This article was originally published in Clinica
Executive Summary
The US FDA has cleared for sale Prosurg's bioabsorbable urethral sling products for treating female incontinence. The pubo-vaginal and sub-urethral vaginal BioSling devices have an absorption rate of 18-24 months, providing urethral support for an extended period of time, says the Silicon Valley, California firm. The self-anchoring products are made from long-lasting biocompatible polymers, which minimise the risk of infection, urethral erosion and foreign body reaction, the company adds.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.